<?xml version="1.0" encoding="UTF-8"?>
<p>Our literature review
 <xref rid="CIT0016" ref-type="bibr">
  <sup>16–18</sup>
 </xref> revealed several CDKIs bearing similar pharmacophoric groups which include two aryl/heterocyclic rings, two carbonyl groups, and a five-membered pyrazole/imidazole core, 
 <xref ref-type="fig" rid="F0001">Figure 1</xref>. Among these inhibitors, compound 
 <bold>1</bold> exhibited moderate inhibitory activity against CDK-2 with an IC
 <sub>50</sub> value of 0.324 μM
 <sup>15</sup>. Compound 
 <bold>1</bold> also exhibited inhibitory activity against CDK-1/4. The study of structure–activity relationship of compound 
 <bold>1</bold> revealed improvement in CDK-2 inhibitory activity on replacement of the ketone oxygen by sulfur
 <xref rid="CIT0015" ref-type="bibr">
  <sup>15</sup>
 </xref>.
</p>
